187 related articles for article (PubMed ID: 38203736)
1. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts.
Wang S; Wei W; Yuan Y; Guo J; Liang D; Zhao X
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203736
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
[TBL] [Abstract][Full Text] [Related]
3. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models.
Yuan Y; Fan J; Liang D; Wang S; Luo X; Zhu Y; Liu N; Xiang T; Zhao X
Transl Oncol; 2024 Jan; 39():101803. PubMed ID: 37897831
[TBL] [Abstract][Full Text] [Related]
4. GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells.
Ibanez J; Hebbar N; Thanekar U; Yi Z; Houke H; Ward M; Nevitt C; Tian L; Mack SC; Sheppard H; Chiang J; Velasquez MP; Krenciute G
Cell Rep Med; 2023 Nov; 4(11):101297. PubMed ID: 37992682
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
7. Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
Hernandez I; Cohen M
Cancer Lett; 2022 Jan; 524():1-14. PubMed ID: 34637844
[TBL] [Abstract][Full Text] [Related]
8. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
10. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
11. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia.
Yu W; Zhang H; Yuan Y; Tang J; Chen X; Liu T; Zhao X
Front Cell Dev Biol; 2022; 10():928140. PubMed ID: 35990606
[TBL] [Abstract][Full Text] [Related]
13. T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice.
Sonzogni O; Zak DE; Sasso MS; Lear R; Muntzer A; Zonca M; West K; Champion BR; Rottman JB
Oncoimmunology; 2022; 11(1):2029070. PubMed ID: 35154906
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
15. Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer.
Farshbaf M; Khosroushahi AY; Mojarad-Jabali S; Zarebkohan A; Valizadeh H; Walker PR
J Control Release; 2020 Dec; 328():932-941. PubMed ID: 33129921
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
17. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer.
Tian W; Zhao J; Wang W
Lung; 2023 Oct; 201(5):489-497. PubMed ID: 37823901
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
